Deregulation of protein and lipid kinase activities leads to a variety of pathologies, ranging
from cancer inflammatory diseases, diabetes, infectious diseases, and cardiovascular …

Highlights•Kinases constitute a very successful target area comprising now 28 approved
inhibitors.•Despite this success only few first in class kinase inhibitors entered clinical testing …

With the advent of the Type II kinase inhibitor imatinib (Gleevec) for treatment against
cancer, rational design of tailored molecules has brought a revolution in medicinal chemistry …

Deregulation of kinase activity has emerged as a major mechanism by which cancer cells
evade normal physiological constraints on growth and survival. To date, 11 kinase inhibitors …

Protein kinases have emerged as the most important class of targets in oncology drug
discovery because of their major roles in regulating cellular growth and survival. At least, 11 …

Highlights•A dramatic increase in the approval of small molecule kinase inhibitors
(SMKIs).•The molecular weight of most approved SMKIs is in the range of 400–600.•The …

Protein and lipid kinases fulfill essential roles in many signaling pathways that regulate
normal cell functions. Deregulation of these kinase activities lead to a variety of pathologies …

An expert guide to targeting protein kinases in cancer therapy Research has shown that
protein kinases can instigate the formation and spread of cancer when they transmit faulty …

In various types of malignancies, conventional forms of therapy (surgery, radiation and
chemotherapy) are often ineffective, as well as harmful. In the last few years, a convergence …

Tremendous progress has been made by utilizing kinase inhibitors in oncology, and these
agents continue to pave the way into other areas of medicine. There are, however, many …